At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
BQ-123drug
Likely dose
BQ-123 120 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of Endothelin in Pulmonary Hypertension
In Brief
A Phase 2 clinical trial evaluating BQ-123 for Pulmonary Hypertension. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 1999
First PostedSep 2008
Primary CompletionOct 2010
Study CompletionJun 2011
TodayJul 2026
First PostedSep 25, 2008
Enrollment StartFeb 1, 1999
Primary CompletionOct 1, 2010
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11.7 yearsPosted 17.8 years ago
Interventions
BQ-123drug
6-120 µg/min